摘要
Clostridium difficile infection (CDI) remains a major public health issue, and fecal microbiota transplantation (FMT) has become one of the standard therapies for recurrent or refractory CDI. When compared to medical therapies, such as metronidazole or vancomycin, FMT has a high rate of treatment response with acceptable safety and efficiency. Following promulgation of the amendments in September 2018 in Taiwan, FMT has been indicated for recurrent or refractory CDI. The Taiwan Microbiota Consortium contributed to the Taiwan FMT Expert Consensus, which established basic norms and stipulated essential principles, including the indications for transplantation, eligible locations and personnel, donor screening policies, fecal sample handling, and post-FMT follow-up. However, establishing an eligible FMT team in a qualified hospital remains a clinical challenge, and the requirement for facilities and well-screened donors impedes the implementation of FMT. In this review, we aim to provide domestic FMT teams with explicit instructions to facilitate realization and increase the practice of FMT. Based on the Taiwan FMT Expert Consensus and current regulations, we performed a literature review and integrated the experiences of Taiwanese multidisciplinary experts into this article. The content intends to offer clinicians up-to-date evidence and highlight the essential points of FMT.
| 原文 | English |
|---|---|
| 頁（從 - 到） | 841-850 |
| 頁數 | 10 |
| 期刊 | Journal of Microbiology, Immunology and Infection |
| 卷 | 52 |
| 發行號 | 6 |
| DOIs | |
| 出版狀態 | Published - 2019 十二月 |
指紋
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology and Microbiology(all)
- Microbiology (medical)
- Infectious Diseases
引用此文
}
Fecal microbiota transplantation for Clostridium difficile infection in Taiwan : Establishment and implementation. / Lin, Tien Ching; Hung, Yuan Pin; Ko, Wen Chien; Ruan, Jhen Wei.
於: Journal of Microbiology, Immunology and Infection, 卷 52, 編號 6, 12.2019, p. 841-850.研究成果: Review article
TY - JOUR
T1 - Fecal microbiota transplantation for Clostridium difficile infection in Taiwan
T2 - Establishment and implementation
AU - Lin, Tien Ching
AU - Hung, Yuan Pin
AU - Ko, Wen Chien
AU - Ruan, Jhen Wei
PY - 2019/12
Y1 - 2019/12
N2 - Clostridium difficile infection (CDI) remains a major public health issue, and fecal microbiota transplantation (FMT) has become one of the standard therapies for recurrent or refractory CDI. When compared to medical therapies, such as metronidazole or vancomycin, FMT has a high rate of treatment response with acceptable safety and efficiency. Following promulgation of the amendments in September 2018 in Taiwan, FMT has been indicated for recurrent or refractory CDI. The Taiwan Microbiota Consortium contributed to the Taiwan FMT Expert Consensus, which established basic norms and stipulated essential principles, including the indications for transplantation, eligible locations and personnel, donor screening policies, fecal sample handling, and post-FMT follow-up. However, establishing an eligible FMT team in a qualified hospital remains a clinical challenge, and the requirement for facilities and well-screened donors impedes the implementation of FMT. In this review, we aim to provide domestic FMT teams with explicit instructions to facilitate realization and increase the practice of FMT. Based on the Taiwan FMT Expert Consensus and current regulations, we performed a literature review and integrated the experiences of Taiwanese multidisciplinary experts into this article. The content intends to offer clinicians up-to-date evidence and highlight the essential points of FMT.
AB - Clostridium difficile infection (CDI) remains a major public health issue, and fecal microbiota transplantation (FMT) has become one of the standard therapies for recurrent or refractory CDI. When compared to medical therapies, such as metronidazole or vancomycin, FMT has a high rate of treatment response with acceptable safety and efficiency. Following promulgation of the amendments in September 2018 in Taiwan, FMT has been indicated for recurrent or refractory CDI. The Taiwan Microbiota Consortium contributed to the Taiwan FMT Expert Consensus, which established basic norms and stipulated essential principles, including the indications for transplantation, eligible locations and personnel, donor screening policies, fecal sample handling, and post-FMT follow-up. However, establishing an eligible FMT team in a qualified hospital remains a clinical challenge, and the requirement for facilities and well-screened donors impedes the implementation of FMT. In this review, we aim to provide domestic FMT teams with explicit instructions to facilitate realization and increase the practice of FMT. Based on the Taiwan FMT Expert Consensus and current regulations, we performed a literature review and integrated the experiences of Taiwanese multidisciplinary experts into this article. The content intends to offer clinicians up-to-date evidence and highlight the essential points of FMT.
UR - http://www.scopus.com/inward/record.url?scp=85073003544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073003544&partnerID=8YFLogxK
U2 - 10.1016/j.jmii.2019.08.009
DO - 10.1016/j.jmii.2019.08.009
M3 - Review article
C2 - 31607571
AN - SCOPUS:85073003544
VL - 52
SP - 841
EP - 850
JO - Journal of Microbiology, Immunology and Infection
JF - Journal of Microbiology, Immunology and Infection
SN - 1684-1182
IS - 6
ER -